|

GI-101A Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 1/2: 1

Top Sponsors

  • GI Innovation, Inc.1

Indications

  • Clear Cell Renal Cell Cancer (ccRCC)1
  • Squamous-Cell Non-Small Cell Lung Cancer1
  • Microsatellite Stable Colorectal Carcinoma1
  • Urinary Bladder Cancer1
  • Renal Cell Carcinoma1

New York, New York1 trial

GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors

Tisch Cancer Institute (TCI), Icahn School of Medicine

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.